论文部分内容阅读
目的观察厄贝沙坦氢氯噻嗪联合美托洛尔治疗重症心力衰竭的效果,探索最佳治疗措施。方法选择我科收治的116例重症心力衰竭患者,根据患者的入组顺序进行分组,予以厄贝沙坦氢氯噻嗪联合美托洛尔治疗者为观察组,予以常规治疗者为对照组,每组各58例。治疗后对两组患者进行疗效判定以及临床指标的观测。结果观察组患者,显效30例,有效26例,无效者2例,有效率96.55%,高于对照组有效率82.76%,差异具有统计学意义(P<0.05)。治疗前,两组患者各指标比较均无统计学意义(P>0.05);治疗后,与对照组比较,观察组的LVESD、LVEDV降低明显,LVEF则增加明显,差异均具统计学意义(P<0.05)。结论厄贝沙坦氢氯噻嗪联合美托洛尔治疗重症心力衰竭疗效较好,具有临床推广意义。
Objective To observe the effect of irbesartan and hydrochlorothiazide combined with metoprolol in the treatment of severe heart failure and explore the best treatment. Methods One hundred and sixty-six patients with severe heart failure who were admitted to our department were divided into groups according to the patients’ enrollment order, treated with irbesartan hydrochlorothiazide combined with metoprolol as observation group and those treated with conventional therapy as control group 58 cases. After treatment, the two groups of patients to determine the efficacy and clinical indicators observed. Results In observation group, 30 cases were markedly effective, 26 cases were effective and 2 cases were ineffective. The effective rate was 96.55%, which was higher than that of the control group (82.76%). The difference was statistically significant (P <0.05). Before treatment, there was no significant difference between the two groups (P> 0.05). After treatment, the LVESD and LVEDV in the observation group decreased significantly and the LVEF increased significantly (P <0.05). Conclusion Irbesartan hydrochlorothiazide combined with metoprolol in the treatment of severe heart failure better effect, with clinical significance.